Zusammenfassung
Hintergrund
Die Weltgesundheitsorganisation (WHO) plant eine Aktualisierung der WHO-Klassifikation maligner Lymphome.
Ziel der Arbeit
Darstellung neuer diagnostisch und klinisch relevanter Erkenntnisse aus dem Bereich der malignen Lymphome.
Material und Methoden
Eine selektive Literaturrecherche (http://www.ncbi.nlm.nih.gov) wurde mit den praktischen Erfahrungen der Autoren aus der klinisch-pathologischen Diagnostik kombiniert.
Ergebnisse
Vermehrt wurden in den letzten Jahren frühe Läsionen maligner Lymphome beschrieben, deren Progressionspotenzial z. T. noch unklar ist. Neue Grenzziehungen ergeben sich v. a. im Bereich der T-Zell-Lymphome. Prognostische Subgruppen lassen sich jedoch auch in der heterogenen Gruppe der diffusen großzelligen B-Zell-Lymphome abgrenzen. Neu beschriebene genetische Veränderungen erleichtern die differenzialdiagnostische Abgrenzung morphologisch ähnlicher Erkrankungen und können einen wichtigen diagnostischen Baustein darstellen.
Schlussfolgerungen
Grundlagenwissenschaftliche Erkenntnisse der letzten Jahre finden mehr und mehr Anwendung in der Diagnose von Lymphomen. Die Aktualisierung der WHO-Klassifikation wird dieser Entwicklung Rechnung tragen.
Abstract
Background
The World Health Organization (WHO) is planning an update of the WHO classification of malignant lymphomas.
Objective
To present new findings concerning the diagnostics and subclassification of malignant lymphomas.
Material and methods
A selective literature search (http://www.ncbi.nlm.nih.gov) was carried out and combined with the practical experiences of the authors in clinicopathological diagnostics.
Results
In recent years an increasing number of early lesions of malignant lymphomas have been described but the potential malignancy of these lesions is at least for some entities still uncertain. Newly defined entities have been described within the group of T-cell lymphomas and prognostic subgroups have been identified in the heterogeneous group of diffuse large B-cell lymphomas. Detection of mutations facilitates the differential diagnostics of morphologically similar diseases and can be an important component of the diagnostics.
Conclusion
Recent scientific insights are being included more and more into the diagnostics of lymphomas. The update of the WHO classification is a consequence of these developments.
Literatur
Adam P, Schiefer A, Prill S et al (2012) Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues. Mod Pathol 25(12):1629–1636. doi:10.1038/modpathol.2012.117
Arcaini L, Zibellini S, Boveri E et al (2012) The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119(1):188–191. doi:10.1182/blood-2011-08-368209
Attygalle AD, Cabecadas J, Gaulard P et al (2014) Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward – report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology 64(2):171–199. doi:10.1111/his.12251
Aukema SM, Siebert R, Schuuring E et al (2011) Double-hit B-cell lymphomas. Blood 117(8):2319–2331. doi:10.1182/blood-2010-09-297879
Carvajal-Cuenca A, Sua LF, Silva NM et al (2012) In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97(2):270–278. doi:10.3324/haematol.2011.052621
Cong P, Raffeld M, Teruya-Feldstein J et al (2002) In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 99(9):3376–3382
Ganapathi KA, Pittaluga S, Odejide OO et al (2014) Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica 99(9):1421–1432. doi:10.3324/haematol.2014.107938
Grever MR, Blachly JS, Andritsos LA (2014) Hairy cell leukemia: update on molecular profiling and therapeutic advances. Blood Rev 28(5):197–203. doi:10.1016/j.blre.2014.06.003
Hamadeh F, MacNamara SP, Aguilera NS et al (2014) MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. Mod Pathol 28(4):564–574. doi:10.1038/modpathol.2014.120
Henopp T, Quintanilla-Martínez L, Fend F et al (2011) Prevalence of follicular lymphoma in situ in consecutively analysed reactive lymph nodes. Histopathology 59(1):139–142. doi:10.1111/j.1365-2559.2011.03897.x
Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121(12):2253–2263. doi:10.1182/blood-2012-06-435842
Jiménez C, Sebastián E, Chillón MC et al (2013) MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia 27(8):1722–1728. doi:10.1038/leu.2013.62
Koskela HLM, Eldfors S, Ellonen P et al (2012) Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366(20):1905–1913. doi:10.1056/NEJMoa1114885
Kraan W, van Keimpema M, Horlings HM et al (2013) High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 28(3):719–720. doi:10.1038/leu.2013.348
Landgren O (2013) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematol Am Soc Hematol Educ Program 2013:478–487. doi:10.1182/asheducation-2013.1.478
Mamessier E, Song JY, Eberle FC et al (2014) Early lesions of follicular lymphoma: a genetic perspective. Haematologica 99(3):481–488. doi:10.3324/haematol.2013.094474
Oschlies I, Salaverria I, Mahn F et al (2010) Pediatric follicular lymphoma – a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma – Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica 95(2):253–259. doi:10.3324/haematol.2009.013177
Parrilla Castellar ER, Jaffe ES, Said JW et al (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124(9):1473–1480. doi:10.1182/blood-2014-04-571091
Pham-Ledard A, Prochazkova-Carlotti M, Andrique L et al (2013) Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 27:402–411. doi:10.1038/modpathol.2013.156
Poulain S, Boyle EM, Tricot S et al (2015) Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. Br J Haematol 170(2):285–287. doi:10.1111/bjh.13293
Sakata-Yanagimoto M, Enami T, Yokoyama Y et al (2014) Disease-specific mutations in mature lymphoid neoplasms: recent advances. Cancer Sci 105(6):623–629. doi:10.1111/cas.12408
Salaverria I, Philipp C, Oschlies I et al (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 118(1):139–147. doi:10.1182/blood-2011-01-330795
Strati P, Shanafelt TD (2015) Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126(4):454–462
Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4. Aufl. World Health Organization classification of tumours. International Agency for Research on Cancer, Lyon, France
Teixeira LS, Wotherspoon A (2015) The relationship between overt and in-situ lymphoma: a retrospective study of follicular and mantle cell lymphoma cases. Histopathology : doi:10.1111/his.12753
Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305–2315. doi:10.1056/NEJMoa1014209
Treon SP, Xu L, Yang G et al (2012) MYD88 L265P Somatic Mutation in Waldenström’s Macroglobulinemia. N Engl J Med 367(9):826–833. doi:10.1056/NEJMoa1200710
Varettoni M, Arcaini L, Zibellini S et al (2013) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood 121(13):2522–2528. doi:10.1182/blood-2012-09-457101
Wada DA, Law ME, Hsi ED et al (2011) Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol 24(4):596–605. doi:10.1038/modpathol.2010.225
Xi L, Arons E, Navarro W et al (2012) Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 119(14):3330–3332. doi:10.1182/blood-2011-09-379339
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
K. Koch und W. Klapper geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Additional information
Redaktion
W. Hiddemann, München
Rights and permissions
About this article
Cite this article
Koch, K., Klapper, W. Klassifikation maligner Lymphome. Internist 57, 206–213 (2016). https://doi.org/10.1007/s00108-015-0006-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-015-0006-6
Schlüsselwörter
- MYD88-Protein
- BRAF-Protein
- In-situ-Lymphom
- Diffuses großzelliges B-Zell-Lymphom
- Peripheres T-Zell Lymphom